Acarix AB AI Stock Analysis
Want to see SE:ACARIX full AI Analyst Report?
Acarix AB (ACARIX) AI Stock Analysis
Acarix AB
(Nasdaq OMX AB:ACARIX)
The overall score is heavily pressured by severe unprofitability and negative cash flows, which overshadow strong revenue growth. Technicals confirm a persistent downtrend, and the negative P/E ratio offers no valuation support. The debt-free balance sheet is the sole mitigating factor, but it is being rapidly consumed by ongoing losses.
Acarix AB (ACARIX) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 213.86M
- Dividend Yield
- ―
- Average Volume (3M)
- 1.43M
- Price to Earnings (P/E)
- -5.4
- Beta (1Y)
- 0.09
- Revenue Growth
- 40.61%
- EPS Growth
- 32.63%
- Country
- Sweden
- Employees
- 8
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Acarix AB Business Overview & Revenue Model
Company Description
Acarix AB (publ) is a medical technology company that develops and introduces diagnostic solutions for cardiovascular conditions to markets including Germany, Sweden, the Middle East, Switzerland, Austria, and globally. Their key product is the CADSc...
Acarix AB Financial Statement Overview
Summary
Strong 5.5x revenue growth and improving gross margins to 48.8% are offset by deep unprofitability (TTM net margin -387%) and substantial cash burn. The debt-free balance sheet provides a cushion, but equity is eroding rapidly with a -96.1% ROE, making the overall financial health precarious.
Income Statement
35NegativeBalance Sheet
65PositiveCash Flow
30Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.73M | 7.36M | 6.20M | 6.24M | 5.82M | 3.76M |
| Gross Profit | 4.75M | 2.76M | 5.59M | 5.30M | 4.62M | 2.82M |
| EBITDA | -33.84M | -44.53M | -62.63M | -74.62M | -73.78M | -48.28M |
| Net Income | -37.67M | -48.09M | -66.19M | -77.84M | -76.98M | -51.80M |
Balance Sheet | ||||||
| Total Assets | 41.41M | 48.33M | 80.76M | 62.88M | 69.48M | 118.60M |
| Cash, Cash Equivalents and Short-Term Investments | 21.00M | 18.27M | 53.99M | 35.15M | 11.31M | 15.81M |
| Total Debt | 0 | 0 | 0 | 0 | 251.00K | 523.00K |
| Total Liabilities | 3.43M | 10.16M | 5.06M | 11.00M | 17.66M | 18.06M |
| Stockholders Equity | 37.98M | 38.17M | 75.70M | 51.88M | 51.83M | 100.54M |
Cash Flow | ||||||
| Free Cash Flow | -24.04M | -49.14M | -64.25M | -81.37M | -75.02M | -48.05M |
| Operating Cash Flow | -35.79M | -48.38M | -63.33M | -81.37M | -74.87M | -48.01M |
| Investing Cash Flow | -233.00K | -757.00K | -920.00K | 0 | -151.00K | -43.00K |
| Financing Cash Flow | 31.89M | 11.11M | 86.98M | 106.23M | 69.03M | -164.00K |
Acarix AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ACARIX, the sentiment is Negative. The current price of 0.17 is below the 20-day moving average (MA) of 0.18, below the 50-day MA of 0.19, and below the 200-day MA of 0.25, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 41.58 is Neutral, neither overbought nor oversold. The STOCH value of 56.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ACARIX.
Acarix AB Peers Comparison
Overall Rating
SE:SECT.B74Outperform
SE:SEZI55Neutral
SE:BACTI.B53Neutral
SE:MNTC51Neutral
SE:HEART44Neutral
SE:ACARIX41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 74Outperform | SEK 63.88B | 100.12 | 30.26% | 0.70% | 13.94% | 5.70% | |
| 55Neutral | SEK 532.17M | -5.46 | -35.44% | ― | 18.56% | 28.11% | |
| 53Neutral | SEK 523.91M | 83.06 | 1.93% | ― | -0.51% | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 51Neutral | SEK 475.32M | -25.18 | -15.00% | ― | 11.18% | 60.51% | |
| 44Neutral | SEK 135.11M | -2.25 | -54.68% | ― | ― | ― | |
| 41Neutral | SEK 213.86M | -5.42 | -96.06% | ― | 40.61% | 32.63% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:ACARIX | Acarix AB | 0.17 | -0.10 | -36.76% | |
| SE:SEZI | Senzime AB | 3.38 | -1.63 | -32.44% | |
| SE:BACTI.B | Bactiguard Holding AB | 14.95 | -1.05 | -6.56% | |
| SE:SECT.B | Sectra AB Class B | 327.40 | 46.64 | 16.61% | |
| SE:HEART | Scandinavian Real Heart AB | 15.90 | 1.05 | 7.09% | |
| SE:MNTC | Mentice AB | 16.90 | 3.60 | 27.07% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026
